Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy
Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy
Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy
Submitted by
admin
on November 8, 2018 - 12:11pm
Source:
CP Wire
News Tags:
Myonexus
Sarepta Therapeutics
muscular dystrophy
gene therapy
Headline:
Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy
snippet:
In a mouse model, greater than 95% of muscle cells produced the beta-sarcoglycan protein after a single application
Myonexus and Sarepta are advancing four additional candidates
Sarepta has the option to purchase Myonexus at any point during their collaboration
Do Not Allow Advertisers to Use My Personal information
